Clofoctol

Clofoctol

SCHEMBL29397347

CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
USP2 O75604 3/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
MAPT P10636 3/20 1.00
CASP1 P29466 2/20 1.00
ESR1 P03372 2/20 1.00
TP53 P04637 1/20 1.00
PGR P06401 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
AR P10275 1/20 1.00
DRD1 P21728 1/20 1.00
PTGS1 P23219 1/20 1.00
SLC6A2 P23975 1/20 1.00
PDE4A P27815 1/20 1.00
MAPK1 P28482 1/20 1.00
SLC6A4 P31645 1/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clofoctol SCHEMBL147809 1.00 CYP3A4 (1.00) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL71922 0.85 CYP3A4 (0.73) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL16656147 0.80 CYP3A4 (0.66) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL27365508 0.76 CYP3A4 (0.61) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL9082692 0.76 CYP3A4 (0.60) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL27365471 0.75 CYP3A4 (0.60) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL9814995 0.75 KLF10 (0.68) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL5964677 0.75 CYP3A4 (0.65) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL8163543 0.74 MAPT (0.59) CYP3A4MEN1KMT2AUSP2SMN1; SMN2
SCHEMBL10802800 0.74 SMN1; SMN2 (0.58) CYP3A4MEN1KMT2AUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111858888-B Multi-round dialogue system of check-in scene 北京航空航天大学 2023-05-30 CN claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
US-12473252-B2 Processes for the preparation of deuterated D-serine SUN PHARMACEUTICAL INDUSTRIES, INC. (US) 2025-11-18 US disclosed
EP-4570265-A1 VACCINE FOR USE IN PREVENTING INFLAMMATORY CONDITIONS IN COWS Zaklad Badawczo-Wdrozeniowy Osrodka Salmonella "Immunolab" Sp. z o.o. (PL) 2025-06-18 EP disclosed
US-12325707-B2 Process for preparing enantiomerically enriched JAK inhibitors SUN PHARMACEUTICAL INDUSTRIES, INC. (US) 2025-06-10 US disclosed
US-20250042841-A1 PROCESSES FOR THE PREPARATION OF DEUTERATED D-SERINE SUN PHARMACEUTICAL INDUSTRIES, INC. 2025-02-06 US disclosed
US-20240368166-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS SUN PHARMACEUTICAL INDUSTRIES, INC. 2024-11-07 US disclosed
WO-2024223624-A1 NEW CLOFOCTOL FORMULATION Institut National de la Santé et de la Recherche Médicale (FR) 2024-10-31 WO disclosed
US-20240300963-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS SUN PHARMACEUTICAL INDUSTRIES, INC. 2024-09-12 US disclosed
US-12065395-B2 Processes for the preparation of deuterated D-serine SUN PHARMACEUTICAL INDUSTRIES, INC. (US) 2024-08-20 US disclosed
EP-3426182-B1 METHODS AND COMPOSITIONS FOR DENTAL TISSUE REPAIR AND/OR REGENERATION HARVARD COLLEGE (US) 2024-05-01 EP disclosed
CN-110234647-B Oxabicycloheptanes for modulating immune responses 利克斯特生物技术公司 2023-05-23 CN disclosed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO disclosed
US-11622929-B2 Long lasting cosmetic compositions LIVING PROOF, INC. (US) 2023-04-11 US disclosed
US-20220306636-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS SUN PHARMACEUTICAL INDUSTRIES, INC. 2022-09-29 US disclosed
US-20220249741-A1 METHODS AND COMPOSITIONS FOR DENTAL TISSUE REPAIR AND/OR REGENERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2022-08-11 US disclosed
CN-114828848-A Intranasal dantrolene administration for the treatment of alzheimer's disease 宾夕法尼亚大学理事会 2022-07-29 CN disclosed
US-20220213105-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS SUN PHARMACEUTICAL INDUSTRIES, INC. 2022-07-07 US disclosed
US-20220169595-A1 PROCESSES FOR THE PREPARATION OF DEUTERATED D-SERINE SUN PHARMACEUTICAL INDUSTRIES, INC. 2022-06-02 US disclosed
WO-2022036030-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS CONCERT PHARMACEUTICALS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12325707-B2 Process for preparing enantiomerically enriched JAK inhibitors JAK1, JAK2, JAK3 CYP3A4 610/4885MEN1 3569/4885KMT2A 870/4885
US-12473252-B2 Processes for the preparation of deuterated D-serine PSPH, SRR, DHPS CYP3A4 2558/4885MEN1 821/4885KMT2A 3739/4885
US-20220213105-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS JAK1, JAK2, JAK3 CYP3A4 610/4885MEN1 3569/4885KMT2A 870/4885
US-20240300963-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS JAK1, JAK2, JAK3 CYP3A4 610/4885MEN1 3569/4885KMT2A 870/4885
US-12065395-B2 Processes for the preparation of deuterated D-serine PSPH, SRR, DHPS CYP3A4 2558/4885MEN1 821/4885KMT2A 3739/4885
US-20220249741-A1 METHODS AND COMPOSITIONS FOR DENTAL TISSUE REPAIR AND/OR REGENERATION ICAM1, EPCAM, MKI67 CYP3A4 4787/4885MEN1 4420/4885KMT2A 3615/4885
US-11622929-B2 Long lasting cosmetic compositions FABP4, CUTA, PLIN5 CYP3A4 4659/4885MEN1 3120/4885KMT2A 2402/4885
US-20220169595-A1 PROCESSES FOR THE PREPARATION OF DEUTERATED D-SERINE PSPH, SRR, DHPS CYP3A4 2558/4885MEN1 821/4885KMT2A 3739/4885
US-20240368166-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS JAK1, JAK2, JAK3 CYP3A4 610/4885MEN1 3569/4885KMT2A 870/4885
US-20220306636-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS JAK1, JAK2, JAK3 CYP3A4 610/4885MEN1 3569/4885KMT2A 870/4885
US-20250042841-A1 PROCESSES FOR THE PREPARATION OF DEUTERATED D-SERINE PSPH, SRR, DHPS CYP3A4 2558/4885MEN1 821/4885KMT2A 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.